CD47 as a promising therapeutic target in oncology

CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 13; s. 757480
Hlavní autoři: Zhao, Hai, Song, Shuangshuang, Ma, Junwei, Yan, Zhiyong, Xie, Hongwei, Feng, Ying, Che, Shusheng
Médium: Journal Article
Jazyk:angličtina
Vydáno: Frontiers Media S.A 22.08.2022
Témata:
atherosclerosis
cancer immunotherapy
CD47
immune modulation
Immunology
immunotherapies
SIRPα
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Alessandro Poggi, San Martino Hospital (IRCCS), Italy
Reviewed by: Sukhbir Kaur, National Institutes of Health (NIH), United States; David Soto-Pantoja, Wake Forest School of Medicine, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.757480